Why the study?
Recurrent pericarditis is a troublesome complication associated with significant morbidity, where interleukin-1 signaling is central to the pathophysiology of cases with systemic inflammation.
Does IL-1 blockade with rilonacept or anakinra improve outcomes in patients with colchicine-resistant and glucocorticoid-dependent recurrent pericarditis?
Does IL-1 blockade with rilonacept or anakinra improve outcomes in patients with colchicine-resistant and glucocorticoid-dependent recurrent pericarditis?
IL-1 blockers such as anakinra and rilonacept are effective therapeutic options for managing recurrences and improving quality of life in patients with refractory recurrent pericarditis.
Answers are grounded in this paper and cite their sources.
Supports IL-1 blockade in refractory recurrent pericarditis; leaves open need for confirmatory RCTs before practice change.
Recurrent pericarditis (RP) is the most troublesome complication of acute pericarditis reflecting an unresolving inflammation of the pericardial sac around the heart and associated with significant morbidity. Recent studies have shown interleukin-1 (IL-1) signaling to be central to the pathophysiology of cases of RP with evidence of activation of systemic inflammation. We herein review the literature and clinical trials discussing the utility of IL-1 blockade for RP. The early experience of IL-1 blockade with anakinra (Kineret) and its favorable safety profile paved the way for the clinical development of rilonacept (Arcalyst) and subsequent approval by the US FDA for RP. In patients with RP who have become colchicine-resistant and glucocorticoid-dependent, IL-1 blockade with rilonacept or anakinra effectively treats recurrences and prevents future flares and significantly improves quality of life.
No takes yet. Share an insight, caveat, or question.
Thomas et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: